Showing results (311-320 of 439) with videos related to
Sort By:
Pageof 44
Journal of the American College of Cardiology|September 1, 2024
Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR ProgramMilton Packer, João Pedro Ferreira, Javed Butler, et al.Journal of the American College of Cardiology|May 10, 2023
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk CategoriesJaved Butler, Milton Packer, Tariq Jamal Siddiqi, et al.Journal of the American College of Cardiology|September 15, 2004
Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysisEugenia Nikolsky, Roxana Mehran, Amir Halkin, et al.European Heart Journal|March 4, 2025
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Andrew Coats, et al.International Journal of Cardiology|July 28, 2017
Characteristics and outcomes of medically managed patients with non-ST-segment elevation acute coronary syndromes: Insights from the multinational EPICOR Asia studyChee Tang Chin, Tiong K Ong, Rungroj Krittayaphong, et al.Circulation|December 23, 2009
Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trialStuart J Pocock, Roxana Mehran, Tim C Clayton, et al.European Heart Journal|March 17, 2012
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?Faiez Zannad, Wendy Gattis Stough, Stuart J Pocock, et al.Journal of the American College of Cardiology|January 5, 2008
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trialsStuart J Pocock, Alexandra J Lansky, Roxana Mehran, et al.Journal of the American College of Cardiology|January 10, 2015
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trialsGregg W Stone, Roxana Mehran, Patrick Goldstein, et al.European Journal of Heart Failure|April 2, 2010
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programmeNathaniel M Hawkins, Duolao Wang, Mark C Petrie, et al.Pageof 44